| . | Cohort 1 . | Cohort 2 (n = 464) . | P-valued . | P-valuee . | ||
|---|---|---|---|---|---|---|
| . | Training set (n = 679) . | Test set (n = 291) . | All (n = 970) . | |||
| Demographic data | ||||||
| Age, mean (SD), years | 41.1 (7.2) | 40.9 (7.1) | 41.0 (7.2) | 61.0 (14.2) | 0.583 | <0.001c |
| Male sex, no. (%) | 466 (68.6%) | 198 (68.0%) | 664 (68.5%) | 266 (57.3%) | 0.856 | <0.001c |
| BMI, mean (SD), kg/m2 | 26.5 (3.4) | 26.6 (3.5) | 26.5 (3.4) | 26.1 (3.7) | 0.657 | 0.065 |
| WHR, mean (SD), % | 87.4 (6.0) | 88.0 (6.3) | 87.6 (6.1) | 91.0 (7.3) | 0.182 | <0.001c |
| Current smoker, no. (%) | 164 (24.2%) | 68 (23.4%) | 232 (23.9%) | 22 (4.7%) | 0.793 | <0.001c |
| Office BP parameters | ||||||
| Office SBP, mean (SD), mmHg | 126.4 (14.6) | 125.5 (14.3) | 126.1 (14.5) | 131.3 (16.6) | 0.352 | <0.001c |
| Office DBP, mean (SD), mmHg | 85.3 (11.3) | 84.1 (12.6) | 84.9 (11.7) | 81.8 (10.5) | 0.163 | <0.001c |
| Office PP, mean (SD), mmHg | 41.1 (9.9) | 41.3 (9.5) | 41.2 (9.8) | 49.5 (14.4) | 0.761 | <0.001c |
| Antihypertensive drug usage | ||||||
| ACEI/ARB, no. (%) | 292 (43.0%) | 118 (40.5%) | 410 (42.3) | 307 (66.2%) | 0.478 | <0.001c |
| Beta-blocker, no. (%) | 305 (44.9%) | 132 (45.4%) | 437 (45.1%) | 109 (23.5%) | 0.899 | <0.001c |
| CCB, no. (%) | 298 (43.9%) | 107 (36.8%) | 405 (41.8%) | 344 (74.1%) | 0.039c | <0.001c |
| Thiazide, no. (%) | 109 (16.1%) | 48 (16.5%) | 157 (16.2%) | 89 (19.2%) | 0.864 | 0.366 |
| Spironolactone, no. (%) | 7 (1.0%) | 0 (0.0%) | 7 (0.7%) | 6 (1.3%) | 0.082 | 0.169 |
| Alpha-blocker, no. (%) | 16 (2.4%) | 6 (2.1%) | 22 (2.3%) | 21 (4.5%) | 0.778 | 0.062 |
| Biochemical profiles | ||||||
| TC, mean (SD), mg/dL | 194.7 (34.6) | 198.3 (37.2) | 195.8 (35.4) | 184.0 (30.8) | 0.161 | <0.001c |
| TG, mean (SD), mg/dL | 164.4 (112.0) | 170.1 (112.7) | 166.1 (112.2) | 127.7 (80.4) | 0.465 | <0.001c |
| HDL-C, mean (SD), mg/dL | 45.5 (11.9) | 45.3 (12.5) | 45.4 (12.1) | 49.0 (13.1) | 0.825 | <0.001c |
| LDL-C, mean (SD), mg/dL | 124.9 (30.8) | 128.3 (32.7) | 126.0 (31.4) | 111.8 (27.1) | 0.131 | <0.001c |
| Creatinine, mean (SD), mg/dL | 0.8 (0.2) | 0.8 (0.2) | 0.8 (0.2) | 0.9 (0.2) | 0.955 | 0.966 |
| Biochemical profiles (continued) | ||||||
| eGFR, mean (SD), mL/min/1.73 m2 | 129.9 (38.5) | 128.1 (37.8) | 129.4 (38.3) | 87.2 (19.4) | 0.499 | <0.001c |
| Sodium, mean (SD), mmol/L | 141.2 (2.7) | 141.4 (2.5) | 141.3 (2.6) | 140.9 (2.4) | 0.239 | 0.021c |
| Potassium, mean (SD), mmol/L | 4.0 (0.3) | 4.1 (0.3) | 4.0 (0.3) | 3.9 (0.6) | 0.046c | <0.001c |
| ALT, mean (SD), U/L | 27.4 (19.2) | 27.9 (19.4) | 27.6 (19.3) | 26.1 (16.4) | 0.747 | 0.371 |
| UA, mean (SD), mg/dL | 6.6 (1.7) | 6.7 (1.7) | 6.6 (1.7) | 6.0 (1.5) | 0.296 | <0.001c |
| Fasting glucose, mean (SD), mg/dL | 98.1 (9.4) | 98.1 (8.7) | 98.1 (9.2) | 100.7 (18.4) | 0.993 | <0.001c |
| Aldosterone, mean (SD), pg/mL | 223.7 (109.5) | 232.9 (144.4) | 226.5 (121.0) | 122.6 (31.6) | 0.327 | <0.001c |
| Ambulatory BP parameters | ||||||
| 24 h SBP, mean (SD), mmHg | 123.4 (12.4) | 122.9 (11.6) | 123.2 (12.2) | 121.5 (11.4) | 0.603 | 0.029c |
| 24 h DBP, mean (SD), mmHg | 82.8 (9.5) | 81.9 (9.5) | 82.6 (9.5) | 73.1 (8.3) | 0.176 | <0.001c |
| Daytime SBP, mean (SD), mmHg | 126.1 (13.0) | 125.9 (12.1) | 126.1 (12.7) | 123.4 (11.7) | 0.790 | 0.001c |
| Daytime DBP, mean (SD), mmHg | 85.2 (10.0) | 84.3 (9.8) | 84.9 (9.9) | 74.7 (8.5) | 0.211 | <0.001c |
| Night-time SBP, mean (SD), mmHg | 114.3 (12.9) | 113.3 (12.4) | 114.0 (12.8) | 117.0 (12.9) | 0.258 | <0.001c |
| Night-time DBP, mean (SD), mmHg | 75.1 (9.8) | 74.0 (10.4) | 74.7 (10.0) | 69.4 (9.3) | 0.130 | <0.001c |
| WCH/WUCH by definition Aa, no. (%) | 55 (8.1%) | 24 (8.2%) | 79 (8.1%) | 118 (25.4%) | 0.939 | <0.001c |
| WCH/WUCH by definition Bb, no. (%) | 17 (2.5%) | 8 (2.7%) | 25 (2.6%) | 45 (9.7%) | 0.825 | <0.001c |
| . | Cohort 1 . | Cohort 2 (n = 464) . | P-valued . | P-valuee . | ||
|---|---|---|---|---|---|---|
| . | Training set (n = 679) . | Test set (n = 291) . | All (n = 970) . | |||
| Demographic data | ||||||
| Age, mean (SD), years | 41.1 (7.2) | 40.9 (7.1) | 41.0 (7.2) | 61.0 (14.2) | 0.583 | <0.001c |
| Male sex, no. (%) | 466 (68.6%) | 198 (68.0%) | 664 (68.5%) | 266 (57.3%) | 0.856 | <0.001c |
| BMI, mean (SD), kg/m2 | 26.5 (3.4) | 26.6 (3.5) | 26.5 (3.4) | 26.1 (3.7) | 0.657 | 0.065 |
| WHR, mean (SD), % | 87.4 (6.0) | 88.0 (6.3) | 87.6 (6.1) | 91.0 (7.3) | 0.182 | <0.001c |
| Current smoker, no. (%) | 164 (24.2%) | 68 (23.4%) | 232 (23.9%) | 22 (4.7%) | 0.793 | <0.001c |
| Office BP parameters | ||||||
| Office SBP, mean (SD), mmHg | 126.4 (14.6) | 125.5 (14.3) | 126.1 (14.5) | 131.3 (16.6) | 0.352 | <0.001c |
| Office DBP, mean (SD), mmHg | 85.3 (11.3) | 84.1 (12.6) | 84.9 (11.7) | 81.8 (10.5) | 0.163 | <0.001c |
| Office PP, mean (SD), mmHg | 41.1 (9.9) | 41.3 (9.5) | 41.2 (9.8) | 49.5 (14.4) | 0.761 | <0.001c |
| Antihypertensive drug usage | ||||||
| ACEI/ARB, no. (%) | 292 (43.0%) | 118 (40.5%) | 410 (42.3) | 307 (66.2%) | 0.478 | <0.001c |
| Beta-blocker, no. (%) | 305 (44.9%) | 132 (45.4%) | 437 (45.1%) | 109 (23.5%) | 0.899 | <0.001c |
| CCB, no. (%) | 298 (43.9%) | 107 (36.8%) | 405 (41.8%) | 344 (74.1%) | 0.039c | <0.001c |
| Thiazide, no. (%) | 109 (16.1%) | 48 (16.5%) | 157 (16.2%) | 89 (19.2%) | 0.864 | 0.366 |
| Spironolactone, no. (%) | 7 (1.0%) | 0 (0.0%) | 7 (0.7%) | 6 (1.3%) | 0.082 | 0.169 |
| Alpha-blocker, no. (%) | 16 (2.4%) | 6 (2.1%) | 22 (2.3%) | 21 (4.5%) | 0.778 | 0.062 |
| Biochemical profiles | ||||||
| TC, mean (SD), mg/dL | 194.7 (34.6) | 198.3 (37.2) | 195.8 (35.4) | 184.0 (30.8) | 0.161 | <0.001c |
| TG, mean (SD), mg/dL | 164.4 (112.0) | 170.1 (112.7) | 166.1 (112.2) | 127.7 (80.4) | 0.465 | <0.001c |
| HDL-C, mean (SD), mg/dL | 45.5 (11.9) | 45.3 (12.5) | 45.4 (12.1) | 49.0 (13.1) | 0.825 | <0.001c |
| LDL-C, mean (SD), mg/dL | 124.9 (30.8) | 128.3 (32.7) | 126.0 (31.4) | 111.8 (27.1) | 0.131 | <0.001c |
| Creatinine, mean (SD), mg/dL | 0.8 (0.2) | 0.8 (0.2) | 0.8 (0.2) | 0.9 (0.2) | 0.955 | 0.966 |
| Biochemical profiles (continued) | ||||||
| eGFR, mean (SD), mL/min/1.73 m2 | 129.9 (38.5) | 128.1 (37.8) | 129.4 (38.3) | 87.2 (19.4) | 0.499 | <0.001c |
| Sodium, mean (SD), mmol/L | 141.2 (2.7) | 141.4 (2.5) | 141.3 (2.6) | 140.9 (2.4) | 0.239 | 0.021c |
| Potassium, mean (SD), mmol/L | 4.0 (0.3) | 4.1 (0.3) | 4.0 (0.3) | 3.9 (0.6) | 0.046c | <0.001c |
| ALT, mean (SD), U/L | 27.4 (19.2) | 27.9 (19.4) | 27.6 (19.3) | 26.1 (16.4) | 0.747 | 0.371 |
| UA, mean (SD), mg/dL | 6.6 (1.7) | 6.7 (1.7) | 6.6 (1.7) | 6.0 (1.5) | 0.296 | <0.001c |
| Fasting glucose, mean (SD), mg/dL | 98.1 (9.4) | 98.1 (8.7) | 98.1 (9.2) | 100.7 (18.4) | 0.993 | <0.001c |
| Aldosterone, mean (SD), pg/mL | 223.7 (109.5) | 232.9 (144.4) | 226.5 (121.0) | 122.6 (31.6) | 0.327 | <0.001c |
| Ambulatory BP parameters | ||||||
| 24 h SBP, mean (SD), mmHg | 123.4 (12.4) | 122.9 (11.6) | 123.2 (12.2) | 121.5 (11.4) | 0.603 | 0.029c |
| 24 h DBP, mean (SD), mmHg | 82.8 (9.5) | 81.9 (9.5) | 82.6 (9.5) | 73.1 (8.3) | 0.176 | <0.001c |
| Daytime SBP, mean (SD), mmHg | 126.1 (13.0) | 125.9 (12.1) | 126.1 (12.7) | 123.4 (11.7) | 0.790 | 0.001c |
| Daytime DBP, mean (SD), mmHg | 85.2 (10.0) | 84.3 (9.8) | 84.9 (9.9) | 74.7 (8.5) | 0.211 | <0.001c |
| Night-time SBP, mean (SD), mmHg | 114.3 (12.9) | 113.3 (12.4) | 114.0 (12.8) | 117.0 (12.9) | 0.258 | <0.001c |
| Night-time DBP, mean (SD), mmHg | 75.1 (9.8) | 74.0 (10.4) | 74.7 (10.0) | 69.4 (9.3) | 0.130 | <0.001c |
| WCH/WUCH by definition Aa, no. (%) | 55 (8.1%) | 24 (8.2%) | 79 (8.1%) | 118 (25.4%) | 0.939 | <0.001c |
| WCH/WUCH by definition Bb, no. (%) | 17 (2.5%) | 8 (2.7%) | 25 (2.6%) | 45 (9.7%) | 0.825 | <0.001c |
ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; ALT, alanine aminotransferase; BMI, body mass index; BP, blood pressure; CCB, calcium channel blocker; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; PP, pulse pressure; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; UA, uric acid; WCH/WUCH, white-coat hypertension/white-coat uncontrolled hypertension; WHR, waist-to-hip ratio; XGboost, eXtreme Gradient Boosting.
WCH/WUCH by definition A: office BP ≥140/90 mmHg and daytime ambulatory BP <135/85 mmHg.
WCH/WUCH by definition B: office BP ≥140/90 mmHg and 24 h ambulatory mean BP <130/80 mmHg and daytime ambulatory BP <135/85 mmHg and night-time ambulatory BP <120/70 mmHg.
Differences were considered significant when P < 0.05.
P-value between the training set and test set.
P-value between the cohort one and cohort two.
| . | Cohort 1 . | Cohort 2 (n = 464) . | P-valued . | P-valuee . | ||
|---|---|---|---|---|---|---|
| . | Training set (n = 679) . | Test set (n = 291) . | All (n = 970) . | |||
| Demographic data | ||||||
| Age, mean (SD), years | 41.1 (7.2) | 40.9 (7.1) | 41.0 (7.2) | 61.0 (14.2) | 0.583 | <0.001c |
| Male sex, no. (%) | 466 (68.6%) | 198 (68.0%) | 664 (68.5%) | 266 (57.3%) | 0.856 | <0.001c |
| BMI, mean (SD), kg/m2 | 26.5 (3.4) | 26.6 (3.5) | 26.5 (3.4) | 26.1 (3.7) | 0.657 | 0.065 |
| WHR, mean (SD), % | 87.4 (6.0) | 88.0 (6.3) | 87.6 (6.1) | 91.0 (7.3) | 0.182 | <0.001c |
| Current smoker, no. (%) | 164 (24.2%) | 68 (23.4%) | 232 (23.9%) | 22 (4.7%) | 0.793 | <0.001c |
| Office BP parameters | ||||||
| Office SBP, mean (SD), mmHg | 126.4 (14.6) | 125.5 (14.3) | 126.1 (14.5) | 131.3 (16.6) | 0.352 | <0.001c |
| Office DBP, mean (SD), mmHg | 85.3 (11.3) | 84.1 (12.6) | 84.9 (11.7) | 81.8 (10.5) | 0.163 | <0.001c |
| Office PP, mean (SD), mmHg | 41.1 (9.9) | 41.3 (9.5) | 41.2 (9.8) | 49.5 (14.4) | 0.761 | <0.001c |
| Antihypertensive drug usage | ||||||
| ACEI/ARB, no. (%) | 292 (43.0%) | 118 (40.5%) | 410 (42.3) | 307 (66.2%) | 0.478 | <0.001c |
| Beta-blocker, no. (%) | 305 (44.9%) | 132 (45.4%) | 437 (45.1%) | 109 (23.5%) | 0.899 | <0.001c |
| CCB, no. (%) | 298 (43.9%) | 107 (36.8%) | 405 (41.8%) | 344 (74.1%) | 0.039c | <0.001c |
| Thiazide, no. (%) | 109 (16.1%) | 48 (16.5%) | 157 (16.2%) | 89 (19.2%) | 0.864 | 0.366 |
| Spironolactone, no. (%) | 7 (1.0%) | 0 (0.0%) | 7 (0.7%) | 6 (1.3%) | 0.082 | 0.169 |
| Alpha-blocker, no. (%) | 16 (2.4%) | 6 (2.1%) | 22 (2.3%) | 21 (4.5%) | 0.778 | 0.062 |
| Biochemical profiles | ||||||
| TC, mean (SD), mg/dL | 194.7 (34.6) | 198.3 (37.2) | 195.8 (35.4) | 184.0 (30.8) | 0.161 | <0.001c |
| TG, mean (SD), mg/dL | 164.4 (112.0) | 170.1 (112.7) | 166.1 (112.2) | 127.7 (80.4) | 0.465 | <0.001c |
| HDL-C, mean (SD), mg/dL | 45.5 (11.9) | 45.3 (12.5) | 45.4 (12.1) | 49.0 (13.1) | 0.825 | <0.001c |
| LDL-C, mean (SD), mg/dL | 124.9 (30.8) | 128.3 (32.7) | 126.0 (31.4) | 111.8 (27.1) | 0.131 | <0.001c |
| Creatinine, mean (SD), mg/dL | 0.8 (0.2) | 0.8 (0.2) | 0.8 (0.2) | 0.9 (0.2) | 0.955 | 0.966 |
| Biochemical profiles (continued) | ||||||
| eGFR, mean (SD), mL/min/1.73 m2 | 129.9 (38.5) | 128.1 (37.8) | 129.4 (38.3) | 87.2 (19.4) | 0.499 | <0.001c |
| Sodium, mean (SD), mmol/L | 141.2 (2.7) | 141.4 (2.5) | 141.3 (2.6) | 140.9 (2.4) | 0.239 | 0.021c |
| Potassium, mean (SD), mmol/L | 4.0 (0.3) | 4.1 (0.3) | 4.0 (0.3) | 3.9 (0.6) | 0.046c | <0.001c |
| ALT, mean (SD), U/L | 27.4 (19.2) | 27.9 (19.4) | 27.6 (19.3) | 26.1 (16.4) | 0.747 | 0.371 |
| UA, mean (SD), mg/dL | 6.6 (1.7) | 6.7 (1.7) | 6.6 (1.7) | 6.0 (1.5) | 0.296 | <0.001c |
| Fasting glucose, mean (SD), mg/dL | 98.1 (9.4) | 98.1 (8.7) | 98.1 (9.2) | 100.7 (18.4) | 0.993 | <0.001c |
| Aldosterone, mean (SD), pg/mL | 223.7 (109.5) | 232.9 (144.4) | 226.5 (121.0) | 122.6 (31.6) | 0.327 | <0.001c |
| Ambulatory BP parameters | ||||||
| 24 h SBP, mean (SD), mmHg | 123.4 (12.4) | 122.9 (11.6) | 123.2 (12.2) | 121.5 (11.4) | 0.603 | 0.029c |
| 24 h DBP, mean (SD), mmHg | 82.8 (9.5) | 81.9 (9.5) | 82.6 (9.5) | 73.1 (8.3) | 0.176 | <0.001c |
| Daytime SBP, mean (SD), mmHg | 126.1 (13.0) | 125.9 (12.1) | 126.1 (12.7) | 123.4 (11.7) | 0.790 | 0.001c |
| Daytime DBP, mean (SD), mmHg | 85.2 (10.0) | 84.3 (9.8) | 84.9 (9.9) | 74.7 (8.5) | 0.211 | <0.001c |
| Night-time SBP, mean (SD), mmHg | 114.3 (12.9) | 113.3 (12.4) | 114.0 (12.8) | 117.0 (12.9) | 0.258 | <0.001c |
| Night-time DBP, mean (SD), mmHg | 75.1 (9.8) | 74.0 (10.4) | 74.7 (10.0) | 69.4 (9.3) | 0.130 | <0.001c |
| WCH/WUCH by definition Aa, no. (%) | 55 (8.1%) | 24 (8.2%) | 79 (8.1%) | 118 (25.4%) | 0.939 | <0.001c |
| WCH/WUCH by definition Bb, no. (%) | 17 (2.5%) | 8 (2.7%) | 25 (2.6%) | 45 (9.7%) | 0.825 | <0.001c |
| . | Cohort 1 . | Cohort 2 (n = 464) . | P-valued . | P-valuee . | ||
|---|---|---|---|---|---|---|
| . | Training set (n = 679) . | Test set (n = 291) . | All (n = 970) . | |||
| Demographic data | ||||||
| Age, mean (SD), years | 41.1 (7.2) | 40.9 (7.1) | 41.0 (7.2) | 61.0 (14.2) | 0.583 | <0.001c |
| Male sex, no. (%) | 466 (68.6%) | 198 (68.0%) | 664 (68.5%) | 266 (57.3%) | 0.856 | <0.001c |
| BMI, mean (SD), kg/m2 | 26.5 (3.4) | 26.6 (3.5) | 26.5 (3.4) | 26.1 (3.7) | 0.657 | 0.065 |
| WHR, mean (SD), % | 87.4 (6.0) | 88.0 (6.3) | 87.6 (6.1) | 91.0 (7.3) | 0.182 | <0.001c |
| Current smoker, no. (%) | 164 (24.2%) | 68 (23.4%) | 232 (23.9%) | 22 (4.7%) | 0.793 | <0.001c |
| Office BP parameters | ||||||
| Office SBP, mean (SD), mmHg | 126.4 (14.6) | 125.5 (14.3) | 126.1 (14.5) | 131.3 (16.6) | 0.352 | <0.001c |
| Office DBP, mean (SD), mmHg | 85.3 (11.3) | 84.1 (12.6) | 84.9 (11.7) | 81.8 (10.5) | 0.163 | <0.001c |
| Office PP, mean (SD), mmHg | 41.1 (9.9) | 41.3 (9.5) | 41.2 (9.8) | 49.5 (14.4) | 0.761 | <0.001c |
| Antihypertensive drug usage | ||||||
| ACEI/ARB, no. (%) | 292 (43.0%) | 118 (40.5%) | 410 (42.3) | 307 (66.2%) | 0.478 | <0.001c |
| Beta-blocker, no. (%) | 305 (44.9%) | 132 (45.4%) | 437 (45.1%) | 109 (23.5%) | 0.899 | <0.001c |
| CCB, no. (%) | 298 (43.9%) | 107 (36.8%) | 405 (41.8%) | 344 (74.1%) | 0.039c | <0.001c |
| Thiazide, no. (%) | 109 (16.1%) | 48 (16.5%) | 157 (16.2%) | 89 (19.2%) | 0.864 | 0.366 |
| Spironolactone, no. (%) | 7 (1.0%) | 0 (0.0%) | 7 (0.7%) | 6 (1.3%) | 0.082 | 0.169 |
| Alpha-blocker, no. (%) | 16 (2.4%) | 6 (2.1%) | 22 (2.3%) | 21 (4.5%) | 0.778 | 0.062 |
| Biochemical profiles | ||||||
| TC, mean (SD), mg/dL | 194.7 (34.6) | 198.3 (37.2) | 195.8 (35.4) | 184.0 (30.8) | 0.161 | <0.001c |
| TG, mean (SD), mg/dL | 164.4 (112.0) | 170.1 (112.7) | 166.1 (112.2) | 127.7 (80.4) | 0.465 | <0.001c |
| HDL-C, mean (SD), mg/dL | 45.5 (11.9) | 45.3 (12.5) | 45.4 (12.1) | 49.0 (13.1) | 0.825 | <0.001c |
| LDL-C, mean (SD), mg/dL | 124.9 (30.8) | 128.3 (32.7) | 126.0 (31.4) | 111.8 (27.1) | 0.131 | <0.001c |
| Creatinine, mean (SD), mg/dL | 0.8 (0.2) | 0.8 (0.2) | 0.8 (0.2) | 0.9 (0.2) | 0.955 | 0.966 |
| Biochemical profiles (continued) | ||||||
| eGFR, mean (SD), mL/min/1.73 m2 | 129.9 (38.5) | 128.1 (37.8) | 129.4 (38.3) | 87.2 (19.4) | 0.499 | <0.001c |
| Sodium, mean (SD), mmol/L | 141.2 (2.7) | 141.4 (2.5) | 141.3 (2.6) | 140.9 (2.4) | 0.239 | 0.021c |
| Potassium, mean (SD), mmol/L | 4.0 (0.3) | 4.1 (0.3) | 4.0 (0.3) | 3.9 (0.6) | 0.046c | <0.001c |
| ALT, mean (SD), U/L | 27.4 (19.2) | 27.9 (19.4) | 27.6 (19.3) | 26.1 (16.4) | 0.747 | 0.371 |
| UA, mean (SD), mg/dL | 6.6 (1.7) | 6.7 (1.7) | 6.6 (1.7) | 6.0 (1.5) | 0.296 | <0.001c |
| Fasting glucose, mean (SD), mg/dL | 98.1 (9.4) | 98.1 (8.7) | 98.1 (9.2) | 100.7 (18.4) | 0.993 | <0.001c |
| Aldosterone, mean (SD), pg/mL | 223.7 (109.5) | 232.9 (144.4) | 226.5 (121.0) | 122.6 (31.6) | 0.327 | <0.001c |
| Ambulatory BP parameters | ||||||
| 24 h SBP, mean (SD), mmHg | 123.4 (12.4) | 122.9 (11.6) | 123.2 (12.2) | 121.5 (11.4) | 0.603 | 0.029c |
| 24 h DBP, mean (SD), mmHg | 82.8 (9.5) | 81.9 (9.5) | 82.6 (9.5) | 73.1 (8.3) | 0.176 | <0.001c |
| Daytime SBP, mean (SD), mmHg | 126.1 (13.0) | 125.9 (12.1) | 126.1 (12.7) | 123.4 (11.7) | 0.790 | 0.001c |
| Daytime DBP, mean (SD), mmHg | 85.2 (10.0) | 84.3 (9.8) | 84.9 (9.9) | 74.7 (8.5) | 0.211 | <0.001c |
| Night-time SBP, mean (SD), mmHg | 114.3 (12.9) | 113.3 (12.4) | 114.0 (12.8) | 117.0 (12.9) | 0.258 | <0.001c |
| Night-time DBP, mean (SD), mmHg | 75.1 (9.8) | 74.0 (10.4) | 74.7 (10.0) | 69.4 (9.3) | 0.130 | <0.001c |
| WCH/WUCH by definition Aa, no. (%) | 55 (8.1%) | 24 (8.2%) | 79 (8.1%) | 118 (25.4%) | 0.939 | <0.001c |
| WCH/WUCH by definition Bb, no. (%) | 17 (2.5%) | 8 (2.7%) | 25 (2.6%) | 45 (9.7%) | 0.825 | <0.001c |
ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; ALT, alanine aminotransferase; BMI, body mass index; BP, blood pressure; CCB, calcium channel blocker; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; PP, pulse pressure; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; UA, uric acid; WCH/WUCH, white-coat hypertension/white-coat uncontrolled hypertension; WHR, waist-to-hip ratio; XGboost, eXtreme Gradient Boosting.
WCH/WUCH by definition A: office BP ≥140/90 mmHg and daytime ambulatory BP <135/85 mmHg.
WCH/WUCH by definition B: office BP ≥140/90 mmHg and 24 h ambulatory mean BP <130/80 mmHg and daytime ambulatory BP <135/85 mmHg and night-time ambulatory BP <120/70 mmHg.
Differences were considered significant when P < 0.05.
P-value between the training set and test set.
P-value between the cohort one and cohort two.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
